Summary
Alzheimer’s disease treatment has shifted from symptomatic management to disease modification with the emergence of anti-amyloid beta (Aβ) inhibitors that target the root cause by clearing amyloid plaques.
Biogen/Eisai’s LEQEMBI and Eli Lilly’s KISUNLA are currently the only Aβ-targeting therapies to receive full regulatory approval for the treatment of early Alzheimer's disease in the United States.
Next-generation Aβ inhibitors focus on improved safety, speed, and convenience include Roche’s Trontinemab, Eli Lilly’s Remternetug, Alzheon’s ALZ-801, Acumen’s Sabirnetug, Priavoid's PRI-002, Prothena's PRX012, ProMIS Neurosciences' PMN310, and Merry Li...
